August 4, 2020

Novavax reports promising early trial results of COVID-19 vaccine

Washington (AFP) – US biotech company Novavax on Tuesday announced its experimental COVID-19 vaccine elicited a robust immune response, producing more antibodies than are present in recovered patients, and with generally tolerable side-effects in its early-stage trial.The company was given $1.6 billion by the US government last month to develop and fund the drug under Operation Warp Speed — but in terms of timeline it is behind other firms including Moderna and AstraZeneca which have entered the final stages of their trials.It reported in a press release that the phase one stage of its placeb…


Leave a Reply

Your email address will not be published. Required fields are marked *